Nuritas is a drug discovery company that uses AI to accelerate the identification and validation of bioactive peptides across multiple therapeutic areas, delivering in months, candidate molecules with a high success rates (>60% predicted). Nuritas is the first company in the world to prove AI can take a healthcare product from concept to market, completed in less than 2 years (in partnership with BASF). We are currently addressing several indications across multiple therapeutic areas, including inflammation, diabetes, muscle health, anti-aging, hypertension, and anti-microbials. Nuritas is privately funded with more than $60M raised in 4 years. The science and AI is now validated, with more than 1,000,000 novel peptides discovered in 2018 alone, 2,000 of which are under patent.
Nuritas are proud supporters of the AI Applications in Biopharma Summit.